2-(5-OXo-5,6-dihydro-4h-imidazo[1,2-b][1,2,4]triazol-6-yl)-n-propylacetamide

Catalog No. :
ACBULY625
CAS No. :
1428139-62-1
Molecular Formula :
C9H13N5O2
Molecular Weight :
223.24

IUPAC Name:2-(5-oxo-5,6-dihydro-4H-imidazo[1,2-b][1,2,4]triazol-6-yl)-N-propylacetamide

2-(5-OXo-5,6-dihydro-4h-imidazo[1,2-b][1,2,4]triazol-6-yl)-n-propylacetamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$155.00Login to see priceInquiryInquiry
1g95%$388.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-(5-OXo-5,6-dihydro-4h-imidazo[1,2-b][1,2,4]triazol-6-yl)-n-propylacetamide
IUPAC Name2-(5-oxo-5,6-dihydro-4H-imidazo[1,2-b][1,2,4]triazol-6-yl)-N-propylacetamide
MDL No.MFCD27936969
Molecular FormulaC9H13N5O2
Molecular Weight223.24
SMILESCCCNC(CC1N2N=CN=C2NC1=O)=O
InChI KeyAETYPUQZYAINSW-UHFFFAOYSA-N
Synonym2-(5-oxo-5,6-dihydro-4H-imidazo[1,2-b][1,2,4]triazol-6-yl)-N-propylacetamide;1H-Imidazo[1,2-b][1,2,4]triazole-6-acetamide, 5,6-dihydro-5-oxo-N-propyl-
CAS No.1428139-62-1

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACBULY625 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACGTAQ598 route compound structure diagram
    ACGTAQ598556-53-6 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACBULY625 route product structure diagram
    ACBULY6251428139-62-1
Inquiry

2. ACBULY625 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACGTAQ598 route compound structure diagram
    ACGTAQ598556-53-6 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACBULY625 route product structure diagram
    ACBULY6251428139-62-1
Inquiry

Comments (0)